AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
A Chest study finds that respiratory or red flag symptoms at baseline increase the likelihood of lung cancer diagnosis within one year after screening. A Nature study identifies glucocorticoid-related genes with causal links to non-small cell lung cancer and constructs a multi-omics prognostic model.
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Meta-analysis of 24 trials found chemoimmunotherapy improved survival in PD-L1-high advanced NSCLC. PPIs and antibiotics were linked to worse durvalumab outcomes, and a chronotherapy trial was retracted.
Hengrui Medicine won NMPA clearance for a Phase II NSCLC trial combining SHR-A2009 ADC with adebrelimab or EGFR-TKI, and with partner Kailera reported up to 12.1% weight loss in a Phase II obesity study of oral ribupatide. SHR-A2009 monotherapy NDA is under review for NSCLC, and cumulative R&D on SHR-A2009 has reached RMB 330 million.
ImmunityBio's Q1 2026 product revenue rose 168% to $44.2 million, beating estimates, while the GAAP net loss widened to $632.8 million. The company is advancing a Phase 2 NHL trial and an sBLA for BCG-naïve NMIBC.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
KEYNOTE-942 five-year data: intismeran autogene plus Keytruda reduced melanoma recurrence risk by 49% and kept 68.8% of patients cancer-free versus 49.1% with Keytruda alone. Distant metastasis or death risk fell 59%.
BioNTech reported a Q1 2026 net loss of $622.3 million as revenue declined to $138.0 million and R&D spending rose to $651.6 million. The company expanded its oncology pipeline with five new pivotal trials for pumitamig and announced manufacturing site exits to save $584.9 million annually by 2029.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780591 |
Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer |
NOT_YET_RECRUITING | NA |
| NCT07777822 |
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC |
RECRUITING | PHASE3 |
| NCT07775040 |
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07770100 |
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07756645 |
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants |
NOT_YET_RECRUITING | PHASE3 |
| NCT07748325 |
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC |
RECRUITING | PHASE2 |
| NCT07743723 |
A Study of IOV-5001 in Adults With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07720167 |
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07718139 |
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada |
ACTIVE_NOT_RECRUITING | |
| NCT07710599 |
LKB1 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer: A Retrospective Cohort Study |
ACTIVE_NOT_RECRUITING |
